 HAYWARD, Calif.--BUSINESS WIRE--Arcus Biosciences, Inc. NYSE:RCUS, an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensation Committee of the Companys Board of Directors granted eight new employees options to purchase a total of 58,200 shares of the Companys common stock at an exercise price per share of 36.99, which was the closing price on September 23, 2021. The stock options were granted pursuant to the Compa 